News
-
-
PRESS RELEASE
Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Newron Pharmaceuticals S.p.A. presents compelling additional data from study 008A showcasing the efficacy of evenamide in poorly responding schizophrenia patients. Significant multi-domain benefits observed in PANSS and CGI-C ratings -
-
-
PRESS RELEASE
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Newron Pharmaceuticals S.p.A. announces positive Phase II/III study results of evenamide in schizophrenia patients, meeting primary and key secondary endpoints with good tolerability -
-
-
PRESS RELEASE
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
Newron Pharmaceuticals presented data from study 014/015 and evenamide clinical development outlook at SIRS 2024 Congress, showcasing potential for new TRS treatment options -
-